CHRS - CIK 0001512762
Coherus BioSciences, Inc. (CHRS) reported net income of $168.02M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | $168.02M | +489.4% |
| FY 2024 | $28.51M | +112.0% |
| FY 2023 | -$237.89M | +18.5% |
| FY 2022 | -$291.75M | -1.6% |
| FY 2021 | -$287.10M | -317.1% |
| FY 2020 | $132.24M | +47.2% |
| FY 2019 | $89.83M | +142.9% |
| FY 2018 | -$209.34M | +12.1% |
| FY 2017 |
Coherus BioSciences, Inc. (CHRS) reported net income of $168.02M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2012 and fiscal 2025, Coherus BioSciences, Inc.'s net income grew from -$33.02M to $168.02M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$238.17M |
| -87.0% |
| FY 2016 | -$127.34M | +43.0% |
| FY 2015 | -$223.26M | -156.2% |
| FY 2014 | -$87.13M | -62.5% |
| FY 2013 | -$53.63M | -62.4% |
| FY 2012 | -$33.02M | - |